Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations
<p>This scoping review aims to comprehensively map and critically analyze existing evidence regarding the optimal HBV vaccination strategies—including vaccine types, schedules, immunogenicity, duration of protection, factors influencing seroresponses, and safety—primarily in adults with pre-di...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1852017769257631744 |
|---|---|
| author | Wiwat Chancharoenthana (4662685) |
| author2 | Opas Traitanon (756970) Asada Leelahavanichkul (3161592) Claudio Ronco (983) |
| author2_role | author author author |
| author_facet | Wiwat Chancharoenthana (4662685) Opas Traitanon (756970) Asada Leelahavanichkul (3161592) Claudio Ronco (983) |
| author_role | author |
| dc.creator.none.fl_str_mv | Wiwat Chancharoenthana (4662685) Opas Traitanon (756970) Asada Leelahavanichkul (3161592) Claudio Ronco (983) |
| dc.date.none.fl_str_mv | 2025-08-08T04:00:10Z |
| dc.identifier.none.fl_str_mv | 10.6084/m9.figshare.29857610.v1 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Optimizing_hepatitis_B_vaccination_in_chronic_kidney_disease_a_comprehensive_scoping_review_of_strategies_across_CKD_stages_dialysis_and_transplant_populations/29857610 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Immunology Marine Biology Cancer Science Policy Infectious Diseases Hepatitis B vaccination chronic kidney disease adjuvanted vaccines seroprotection immunogenicity hemodialysis |
| dc.title.none.fl_str_mv | Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>This scoping review aims to comprehensively map and critically analyze existing evidence regarding the optimal HBV vaccination strategies—including vaccine types, schedules, immunogenicity, duration of protection, factors influencing seroresponses, and safety—primarily in adults with pre-dialysis and dialysis-dependent chronic kidney disease (CKD) populations. Patients with CKD are at increased risk of hepatitis B virus (HBV) infection due to the immune dysfunction with frequent blood exposure during invasive procedures, including hemodialysis. Although HBV vaccination is crucial for CKD patients due to the high transmission efficacy of HBV, enhanced regimens or adjuvants are often required because of CKD-induced immune dysfunction. This scoping review followed Joanna Briggs Institute guidelines and the PRISMA-ScR checklist through searching on PubMed, EMBASE, and SCOPUS for English-language studies until August 2024, demonstrated 329 unique records, and 17 studies were included. Accordingly, 4 times of either double-dose simple recombinant vaccine (Engerix-B 40 mcg) or adjuvanted vaccines (e.g., Fendrix<sup>®</sup>, Heplisav-B<sup>®</sup> 20 mcg) demonstrated higher seroprotection rates than the standard conventional schedule (3 times of Engerix-B 20 mcg). Vaccination at pre-dialysis stages (eGFR > 15 mL/min/1.73 m<sup>2</sup>) yielded higher short-term seroprotection (SPR: 63–100% at 1-2 months after the last dose), than in dialysis patients (SPR: 50–89.3% at 1–2 months after the last dose) and the antibody titers were more prominent with adjuvant vaccines than with the nonadjuvant one. In conclusion, the higher doses of vaccination are required in adult patients with CKD; however, data on transplant recipients and pediatric patients are very limited. Large-scale, high-quality randomized controlled trials with long-term immunity monitoring are needed.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_dbde87e4255aebcf40f37ea6e294ddd3 |
| identifier_str_mv | 10.6084/m9.figshare.29857610.v1 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/29857610 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populationsWiwat Chancharoenthana (4662685)Opas Traitanon (756970)Asada Leelahavanichkul (3161592)Claudio Ronco (983)MedicineImmunologyMarine BiologyCancerScience PolicyInfectious DiseasesHepatitis B vaccinationchronic kidney diseaseadjuvanted vaccinesseroprotectionimmunogenicityhemodialysis<p>This scoping review aims to comprehensively map and critically analyze existing evidence regarding the optimal HBV vaccination strategies—including vaccine types, schedules, immunogenicity, duration of protection, factors influencing seroresponses, and safety—primarily in adults with pre-dialysis and dialysis-dependent chronic kidney disease (CKD) populations. Patients with CKD are at increased risk of hepatitis B virus (HBV) infection due to the immune dysfunction with frequent blood exposure during invasive procedures, including hemodialysis. Although HBV vaccination is crucial for CKD patients due to the high transmission efficacy of HBV, enhanced regimens or adjuvants are often required because of CKD-induced immune dysfunction. This scoping review followed Joanna Briggs Institute guidelines and the PRISMA-ScR checklist through searching on PubMed, EMBASE, and SCOPUS for English-language studies until August 2024, demonstrated 329 unique records, and 17 studies were included. Accordingly, 4 times of either double-dose simple recombinant vaccine (Engerix-B 40 mcg) or adjuvanted vaccines (e.g., Fendrix<sup>®</sup>, Heplisav-B<sup>®</sup> 20 mcg) demonstrated higher seroprotection rates than the standard conventional schedule (3 times of Engerix-B 20 mcg). Vaccination at pre-dialysis stages (eGFR > 15 mL/min/1.73 m<sup>2</sup>) yielded higher short-term seroprotection (SPR: 63–100% at 1-2 months after the last dose), than in dialysis patients (SPR: 50–89.3% at 1–2 months after the last dose) and the antibody titers were more prominent with adjuvant vaccines than with the nonadjuvant one. In conclusion, the higher doses of vaccination are required in adult patients with CKD; however, data on transplant recipients and pediatric patients are very limited. Large-scale, high-quality randomized controlled trials with long-term immunity monitoring are needed.</p>2025-08-08T04:00:10ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.6084/m9.figshare.29857610.v1https://figshare.com/articles/dataset/Optimizing_hepatitis_B_vaccination_in_chronic_kidney_disease_a_comprehensive_scoping_review_of_strategies_across_CKD_stages_dialysis_and_transplant_populations/29857610CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/298576102025-08-08T04:00:10Z |
| spellingShingle | Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations Wiwat Chancharoenthana (4662685) Medicine Immunology Marine Biology Cancer Science Policy Infectious Diseases Hepatitis B vaccination chronic kidney disease adjuvanted vaccines seroprotection immunogenicity hemodialysis |
| status_str | publishedVersion |
| title | Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations |
| title_full | Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations |
| title_fullStr | Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations |
| title_full_unstemmed | Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations |
| title_short | Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations |
| title_sort | Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations |
| topic | Medicine Immunology Marine Biology Cancer Science Policy Infectious Diseases Hepatitis B vaccination chronic kidney disease adjuvanted vaccines seroprotection immunogenicity hemodialysis |